Soligenix Inc
SNGX1.130USD
+0.090+8.65%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
11.14MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Soligenix Inc Unternehmen
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Soligenix Inc Informationen
BörsenkürzelSNGX
Name des UnternehmensSoligenix Inc
IPO-datumApr 04, 1994
CEOSchaber (Christopher J)
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeApr 04
Addresse29 Emmons Drive
StadtPRINCETON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl08540
Telefon16095388200
Websitehttps://www.soligenix.com/
BörsenkürzelSNGX
IPO-datumApr 04, 1994
CEOSchaber (Christopher J)
Führungskräfte von Soligenix Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+15132.00%
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+15132.00%
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Fri, Dec 5
Aktualisiert: Fri, Dec 5
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
7.02%
Intracoastal Capital, L.L.C.
4.21%
DRW Securities, LLC
1.70%
Two Sigma Investments, LP
0.87%
The Vanguard Group, Inc.
0.85%
Andere
85.35%
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
7.02%
Intracoastal Capital, L.L.C.
4.21%
DRW Securities, LLC
1.70%
Two Sigma Investments, LP
0.87%
The Vanguard Group, Inc.
0.85%
Andere
85.35%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
8.66%
Corporation
4.21%
Investment Advisor
3.92%
Investment Advisor/Hedge Fund
1.35%
Research Firm
0.51%
Individual Investor
0.16%
Andere
81.19%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
45
1.46M
14.44%
+1.17M
2025Q3
42
242.17K
2.89%
-108.56K
2025Q2
50
150.04K
4.60%
-125.61K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Armistice Capital LLC
708.00K
7.02%
+708.00K
--
Sep 30, 2025
Intracoastal Capital, L.L.C.
425.00K
4.21%
+425.00K
--
Sep 25, 2025
DRW Securities, LLC
171.42K
1.7%
+171.42K
--
Sep 30, 2025
Two Sigma Investments, LP
87.65K
0.87%
+87.65K
--
Sep 30, 2025
The Vanguard Group, Inc.
52.52K
0.52%
+50.34K
+2303.75%
Sep 30, 2025
Sabby Management, LLC
81.00K
0.8%
+81.00K
--
Sep 30, 2025
Renaissance Technologies LLC
72.90K
0.72%
+72.90K
--
Sep 30, 2025
HRT Financial LP
54.67K
0.54%
+54.67K
--
Sep 30, 2025
Virtu Americas LLC
50.86K
0.5%
+50.86K
--
Sep 30, 2025
Banco BTG Pactual SA
46.37K
0.46%
+46.37K
--
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
